MedTrace Logo

PREventing Progression of Adipose Tissue Redistribution

NCT00389194 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2010-06-11

No results posted yet for this study

Summary

The main objective of the study is to assess changes in fat distribution over 48 weeks of treatment in patients who currently successfully use zidovudine (AZT) and lamivudine (3TC) as part of their regimen and who will either continue these antiretrovirals or who will switch these antiretrovirals to tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC). Each of these medications is commonly used for the treatment of HIV-1 infection.

Conditions

  • HIV Infections

Interventions

DRUG

continuing AZT+3TC or switching AZT+3TC to TDF+ FTC

Sponsors & Collaborators

  • Gilead Sciences

    collaborator INDUSTRY

  • International Antiviral Therapy Evaluation Center

    lead OTHER

Principal Investigators

  • Peter Reiss, MD, PhD · Academic Medical Centre

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-04-30
Completion
2008-10-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00389194 on ClinicalTrials.gov